Markets
Capricor Therapeutics Stock Soars 9% After Funding Update — Its Drug Launch Still Awaits Approval
Capricor is preparing an independent launch while cutting roughly 10% of its workforce, even as its quarterly loss widened.
Capricor Therapeutics (CAPR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Capricor is preparing an independent launch while cutting roughly 10% of its workforce, even as its quarterly loss widened.
Earnings
The company cut about 10% of its workforce and slowed other programs as it prepares for a launch contingent on FDA approval.
SEC Filings
Launch and manufacturing preparations pushed quarterly expenses to approximately $44.7 million, even with a roughly 10% workforce cut.
Markets
Deramiocel met its upper-limb trial goal, but a cardiac measure missed statistical significance and FDA approval remains pending.